Sonoma Pharmaceuticals Inc (SNOA)

Sonoma Pharmaceuticals, Inc. is a healthcare company focused on developing and producing stabilized hypochlorous acid (HOCl) products for a range of uses, including wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions. Its portfolio includes products such as Lumacyn, Regenacyn, Reliefacyn, Gramaderm, Epicyn, Levicyn, Celacyn, and Pediacyn, along with lines for eye, nasal, oral, and foot care, animal health, and hospital disinfection. The company also markets solutions such as Microcyn, Ocucyn, Ocudox, Sinudox, Microdacyn60, Podiacyn, MicrocynAH, MicrocynVS, Nanocyn, Acuicyn, MucoClyns, and Endocyn. Formerly known as Oculus Innovative Sciences, it adopted the Sonoma Pharmaceuticals name in December 2016 and was incorporated in 1999. The company is based in Boulder, Colorado, and operates across the United States, Europe, Asia, Latin America, and other international markets.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.